Project Summary
In P20N, we plan to uncover KMT9-dependent immune escape mechanisms in prostate cancer. We will investigate whether KMT9 inhibitors alone or with CXCR2 inhibitors reprogram immune cells and block tumour growth in Pten/Trp53-KO prostates. Moreover, we will explore whether KMT9 loss enhances anti-PD-1-based immunotherapy (Aim 1). We will also investigate whether KMT9 controls immune cell populations in Pten and Pten/Smad4-KO prostates (Aim 2). In addition, we plan to identify the kinase-dependent signalling mechanism regulating translocation of KMT9 to the nucleus during prostate tumourigenesis (Aim 3)
